STIMPulseControl Ancillary Speech Study

NCT ID: NCT06561919

Last Updated: 2025-12-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-09-05

Study Completion Date

2028-07-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Speech assessment is a substudy to the STIMPulseControl study (hereinafter referred to as the main study), where audio recordings of patients voices will be recorded as part of a speech analysis in the main study, for this optional ancillary study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Speech of all study patients enrolled in the STIMPulseControl main study will be recorded at three points of time in a standardized way. Following this ancillary protocol, patients speech will be recorded at the baseline visit (preoperatively), at the 6-months visit and at the 12-months visit postoperatively.

For the baseline speech assessment the same protocol will be performed in chronic medication conditions. At 12-month follow up, we will repeat the speech protocol in chronic medication and stimulation condition. The recordings will be done in each centre in a decentralized way and the audio files will be produced according to a standardized protocol, and assisted by a step-by-step guided speech recording software.

Main aims and hypothesis for automated speech analysis study are safety measures for surgical interventions in PD assessment of parkinsonian (hypokinetic) motor speech features outcome after STN-DBS, assessment of dyskinetic (hyperkinetic) motor speech features outcome after STN-DBS, assessment of capsular speech features outcome after STN-DBS in PD emotional and cognitive speech outcomes to be used in surgical and pharmacological interventions in PD assessment of acoustic and linguistic speech features as proxy for behaviour and cognitive changes in PD, comparison of emotional and cognitive speech outcomes before and 1-year after STN-DBS + BMT vs BMT alone.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease Impulse Control Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DBS-group

Within indication and clinical routine: bilateral high frequency deep brain stimulation of the subthalamic necleus combined with best medical treatment

Group Type OTHER

bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper

Intervention Type PROCEDURE

Best medical treatment according to widely accepted expert consensus Paper

BMT-group

Within indication and clinical routine: best medical treatment

Group Type OTHER

best medical treatment for management of impulse control in Parkinson´s disease according to widely accepted expert consensus paper

Intervention Type DRUG

Best medical treatment according to widely accepted consensus Paper

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper

Best medical treatment according to widely accepted expert consensus Paper

Intervention Type PROCEDURE

best medical treatment for management of impulse control in Parkinson´s disease according to widely accepted expert consensus paper

Best medical treatment according to widely accepted consensus Paper

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

best medical treatment for manangement of impulse control in Parkinson´s disease

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Please refer to main study (STIMPulseControl KKS-313)

Exclusion Criteria

Please refer to main study (STIMPulseControl KKS-313)
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Czech Technical University in Prague

OTHER

Sponsor Role collaborator

Insel Gruppe AG, University Hospital Bern

OTHER

Sponsor Role collaborator

Philipps University Marburg

OTHER

Sponsor Role collaborator

University Hospital Schleswig-Holstein

OTHER

Sponsor Role collaborator

Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)

OTHER

Sponsor Role collaborator

Steffen Paschen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Steffen Paschen

MD

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jan Rusz, Prof.

Role: STUDY_CHAIR

Czech Technical Iniversity in Prague, Faculty of Electrical Engineering

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Cologne

Cologne, , Germany

Site Status RECRUITING

University Hospital Carl Gustav Carus

Dresden, , Germany

Site Status RECRUITING

University Hospital Duesseldorf

Düsseldorf, , Germany

Site Status RECRUITING

University Medical Center Hamburg-Eppendorf

Hamburg, , Germany

Site Status RECRUITING

University Hospital Schleswig-Holstein (UKSH), Campus Kiel

Kiel, , Germany

Site Status RECRUITING

University Hospital of Giessen and Marburg (UKGM), Campus Marburg

Marburg, , Germany

Site Status RECRUITING

Charité Campus Mitte

Mitte, , Germany

Site Status RECRUITING

University Hospital Tuebingen

Tübingen, , Germany

Site Status RECRUITING

University Hospital Wuerzburg

Würzburg, , Germany

Site Status RECRUITING

Amsterdam University Medical Center

Amsterdam, , Netherlands

Site Status RECRUITING

University Hospital of Bern (Inselspital)

Bern, , Switzerland

Site Status RECRUITING

University Hospital Zuerich (USZ)

Zurich, , Switzerland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany Netherlands Switzerland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Steffen Paschen, MD

Role: CONTACT

0049 431 500 23819

Günter Deuschl, Prof. Dr.

Role: CONTACT

0049 431 500 238956

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Michael Barbe, MD

Role: primary

Bjoern Falkenburger, Prof.

Role: primary

Alfons Schnitzler, Prof.

Role: primary

Monika Poetter-Nerger, MD

Role: primary

Steffen Paschen, MD

Role: primary

David Pedrosa, MD

Role: primary

Patricia Krause, MD

Role: primary

Daniel Weiss, Prof.

Role: primary

Jens Volkmann, Prof.

Role: primary

Rob MA De Bie, Prof.

Role: primary

Annabel von der Weide, MD

Role: backup

Ines Debove, MD

Role: primary

Paul Krack, Prof.

Role: backup

Lennart Stieglitz, Prof.

Role: primary

Fabian Buechele, MD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KKS-313-A

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

STEM-Parkinson's Disease
NCT04797611 COMPLETED NA